Treatment of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa in Septic Shock When Susceptibility Results Are Known

This protocol addresses a high-acuity presentation: ventilator-associated pneumonia caused by Pseudomonas aeruginosa in a patient who is in septic shock or at high risk of death, once antibiotic susceptibility testing results are in hand.

Clinical Scenario

The patient has ventilator-associated pneumonia due to Pseudomonas aeruginosa and is either in septic shock or carries a mortality risk above 25%. Critically, antibiotic susceptibility results for the isolate are already available, allowing targeted therapy.

High risk of death has been defined in the supporting evidence as a mortality risk greater than 25%.

Treatment Approach — Partial Overview

The approach calls for susceptibility-guided combination antibiotic therapy targeting the confirmed Pseudomonas isolate. Important restrictions apply to certain antibiotic classes in this setting.

Agent selection, full combination rationale, course length, and all additional clinical guidance are contained in the complete structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciw353

For patients with HAP/VAP due to P. aeruginosa who remain in septic shock or at a high risk for death when the results of antibiotic susceptibility testing are known, we suggest combination therapy using 2 antibiotics to which the isolate is susceptible rather than monotherapy (weak recommendation, very low-quality evidence).

High risk of death in the meta-regression analysis was defined as mortality risk >25%; low risk of death is defined as mortality risk <15%.

View source ↗